## SNA: Snap-On Incorporated - XLI: Industrials

### Executive Summary

No thesis match: MRS_10 1.6% below STRENGTH zone (3.0-6.0%); PEG 1.91 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($338.93)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 3
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Axa S.A. Purchases 58,343 Shares of Snap-On Incorporated $SNA**
- Source: MarketBeat | 20251211T083918 | Somewhat-Bullish | Relevance: 98%
-  Axa S.A. has significantly increased its stake in Snap-On Incorporated, purchasing an additional 58,343 shares and increasing its holdings by 310.5%. This brings Axa S.A.'s total ownership to 77,132 shares, valued at $24,002,000. Other institutional investors have also adjusted their positions in Snap-On, while several company insiders have recently sold shares.

**2. Amundi Buys 26,996 Shares of Snap-On Incorporated $SNA**
- Source: MarketBeat | 20251209T081851 | Bullish | Relevance: 98%
-  Amundi recently increased its stake in Snap-On Incorporated by 12.2%, acquiring an additional 26,996 shares, bringing their total holdings to 247,419 shares valued at approximately $80.7 million. Snap-On also announced a quarterly dividend increase to $2.44 per share, with an annualized yield of 2.8%. The company exceeded quarterly earnings and revenue estimates and holds a consensus "Moderate Buy" rating from analysts with a $365 price target.

**3. Is CapsoVision Showing How Far A Single Capsule Can Take A Med-Tech Company?**
- Source: RTTNews | 20251211T090957 | Somewhat-Bullish | Relevance: 62%
-  CapsoVision Inc. (CV) has garnered significant attention following a sharp rise in trading activity and share price, closing up 32.73% and continuing to climb in after-hours trading. The company, which specializes in endoscopic video imaging devices for GI visualization, is expanding its commercial footprint with products like CapsoCam Plus and advancing new clinical programs such as a Breakthrough Device Designation application for pancreatic cancer detection. CapsoVision's strong financial performance, strategic partnerships, and technological advancements position it as a company to watch in the medical technology sector.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.01M) |
| Sells | 7 ($2.10M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 43.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.5% (-0.0%)
- Blackrock Inc.: 7.8% (-0.8%)
- State Street Corpora: 4.3% (+1.6%)
- Charles Schwab Inves: 3.8% (+0.7%)
- First Trust Advisors: 3.7% (+1.3%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Momentum building: MRS_10 improving +1.3% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.91 elevated, pricing in significant growth expectations. Forward P/E 17.1x stretched relative to 7% growth. Quality metrics strong (margin 20%). Balance sheet: strong liquidity (4.4x), low leverage (D/E 0.43). Insider selling cluster ($2.1M in 90 days), potential headwind. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $18.3B |
| Beta | 0.78 |
| 52W Range | $289.81 - $365.78 |
| Short Interest | 5.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.91 |
| Forward P/E | 17.1 |
| Current P/E | 18.3 |
| YoY Growth | 6.9% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from 0.3% to 1.6% (+1.3% in 5 days), confirming momentum buildup. Below STRENGTH zone by 1.4pp (needs >3.0% for momentum thesis). MRS_5 at 1.1% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (1.33), confirming momentum.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 1.55% (CS: 55) | Neutral |
| RSI_14 | 64.1 | Neutral |
| MACD Histogram | 1.33 | Bullish |
| vs SMA20 | 1.036x | Above |
| vs SMA50 | 1.034x | Above |
| vs SMA200 | 1.070x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $351.49
- **Stop Loss:** $338.93 (3.6% risk)
- **Target:** $364.05 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 109
- **Position Value:** $38,312.41
- **Portfolio %:** 38.31%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-02-05 (Est: $4.92)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $4.64 | $5.02 | +8.1% |
| 2025Q2 | $4.63 | $4.72 | +2.0% |
| 2025Q1 | $4.82 | $4.51 | -6.4% |
| 2024Q4 | $4.79 | $4.82 | +0.5% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*